A transient increase in serum procollagen 1 carboxyterminal peptide following effective treatment in prostate cancer patients with bone metastases.
Procollagen 1 carboxyterminal peptide (P1CP) is thought to be an indicator of new bone formation. The present report demonstrates that effective endocrine therapy induced an initial increase followed by a delayed decrease in serum levels of P1CP and alkaline phosphatase in spite of an immediate decrease in serum PSA and PAP and improvement of clinical symptoms in prostate cancer patients with bone metastases. The transient increase in P1CP and alkaline phosphatase is a healing reaction and is followed by apparent improvement. Short-term effects of endocrine therapy on prostate cancer patients with bone metastases should be comprehensively evaluated based upon the entire spectrum of clinical and laboratory findings including serial changes of serum prostate markers and bone markers as well.
Nakashima
J
J
Department of Urology, Urawa Municipal Hospital, Japan.
Sumitomo
M
M
Miyajima
A
A
Jitsukawa
S
S
Murai
M
M
D000230:Adenocarcinoma / Q000097:blood* / Q000188:drug therapy / Q000556:secondary; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000097:blood / Q000556:secondary*; D004054:Diethylstilbestrol / Q000627:therapeutic use; D004961:Estramustine / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010446:Peptide Fragments / Q000097:blood*; D011347:Procollagen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D011347:Procollagen; C042813:procollagen type I carboxy terminal peptide; D007987:Gonadotropin-Releasing Hormone; D004961:Estramustine; D004054:Diethylstilbestrol; D000469:Alkaline Phosphatase